RHONE-POULENC RORER RESTATES COMMITMENT TO HEMOPHILIA COMMUNITY FOR UNINTERRUPTED SUPPLY OF FACTOR VIII:C
RHONE-POULENC RORER RESTATES COMMITMENT TO HEMOPHILIA
COMMUNITY FOR UNINTERRUPTED SUPPLY OF FACTOR VIII:C
COLLEGEVILLE, Pa., Nov. 21 /PRNewswire/ -- Rhone-Poulenc Rorer Inc. (NYSE: RPR) stated today that it is currently reviewing the motion papers filed by the National Hemophilia Foundation to become party to the factor VIII patent litigation between, on the one side, RPR and The Scripps Research Institute and, on the other side, Baxter International.
The purpose of this review is to enable the company to make an informed and appropriate response to the motion.
This litigation has been pending in the Delaware Court since 1987. On Sept. 12, 1991, RPR filed a preliminary injunction motion requesting the court to mandate an orderly withdrawal of Baxter's ultra pure factor VIII:C product from the marketplace. RPR's motion is directed only to plasma-derived monoclonal human factor VIII:C products. RPR said it is committed to fashioning an injunction which will ensure no interruption in the level of ultra pure factor VIII:C supply to the Hemophilia community. RPR's motion was made in light of the recent decision by the Court of Appeals that reinstated the presumption of validity of the Scripps factor VIII patent. RPR, through its Armour Pharmaceutical Company subsidiary, is the exclusive licensee of the patent.
RPR said it is prepared and willing to meet the increased demand for its ultra pure factor VIII:C Monoclate-P(R) product that may ensue following Baxter's withdrawal of their product from the market. RPR has stated publicly that it will work collaboratively with the Court and with Baxter to ensure no interruption in the level of supply during what is anticipated to be a court-mandated transition period.
"Armour shares with the National Hemophilia Foundation a commitment to serving the needs of people with hemophilia and shares the NHF's top priority of ensuring an adequate and uninterrupted level of supply of ultra pure factor VIII:C in the marketplace," said John Sedor, president and general manager, Armour Pharmaceutical Company. "Regardless of the outcome of the patent litigation dispute, Armour will remain dedicated to providing, without interruption, the highest-quality, safest, and most effective ultra pure factor VIII:C product to people with hemophilia. We will continue to work in partnership with the National Hemophilia Foundation toward that goal."
Rhone-Poulenc Rorer is a global pharmaceutical company dedicated to human health. It operates in the following major therapeutic areas: cardiovascular; bone metabolism/rheumatology; gastroenterology; central nervous system and analgesia; anti-infectives, AIDS, cancer; hypersensitivity; and plasma derivatives. RPR has annualized sales of more than $3.6 billion and an annualized investment in research of more than $440 million. The company operates in all major markets of the world.
/CONTACT: Rhone-Poulenc Rorer media relations, 215-454-3871, or investor relations, 215-454-3851/ CO: Rhone-Poulenc Rorer Inc.; The Scripps Research Institute;
Armour Pharmaceutical Company; National Hemophilia Foundation ST: Pennsylvania IN: MTC SU: CC -- PH024 -- 5893 11/21/91 12:27 EST